Pharma Unscripted

RTI Health Solutions

Pharma Unscripted explores how evidence is evolving across the biopharma landscape—and what that means for patients, access, and decision-making. Through expert-led conversations, the series examines how organizations are generating and applying evidence to bring meaningful therapies to the people who need them most. From patient-centered outcomes and real-world evidence to value demonstration and AI in medical communications, each episode breaks down the trends shaping how therapies move from development to real-world impact.

單集

  1. 6月3日

    The Patient Experience: Evaluating Tolerability in Oncology Treatments

    Why is patient-centered evidence critical in oncology?   As oncology treatments become more targeted and long-term, organizations need evidence that captures real-world patient experience. This episode explores how PROs, tolerability, and patient-centered evidence are shaping adherence, evidence strategy, and market access.       Key Topics: Real-world patient experienceTolerability and treatment burdenPatient-reported outcomes (PROs)Patient-centered evidence strategyAdherence and market access  Guests: Ari Gnanasakthy, Principal Scientist, Patient-Centered Outcomes AssessmentDawn Odom, Vice President, Biostatistics  Learn more about tolerability research

    26 分鐘

  2. 5月8日

    AI in Medical Communications: Why Human Expertise Still Matters

    This episode is part three of a three-part series featured on Fierce Pharma’s The Top Line podcast. AI is transforming medical communications, but it’s not replacing human expertise. In this episode of Pharma Unscripted, we explore how AI is being used across med comms workflows, from literature review to content creation, and where it introduces risk. Accuracy, context, and scientific integrity remain critical, making human oversight essential in an AI-driven environment. Key Topics: AI in medical communicationsScientific accuracy and governanceRisks and limitations of AI-generated contentRole of human expertise Guests: Margaret Mathes, Director of Medical EditingGabby Dardis, Senior Integrated Evidence StrategistFrances Ramsey, Manager of Library Services

    21 分鐘

  3. 5月8日

    From Approval to Value: Evidence Storytelling, HEOR & Market Access

    This episode is part two of a three-part series featured on Fierce Pharma’s The Top Line podcast. Getting a therapy approved is only part of the journey, demonstrating its value is what drives access. In this episode of Pharma Unscripted, we explore how evidence storytelling is becoming critical in biopharma. From real-world evidence (RWE) to health economics and outcomes research (HEOR), organizations must translate complex data into clear, decision-relevant insights. As payers and HTA bodies demand stronger value demonstration, how you communicate evidence can directly impact patient access. Key Topics: Evidence storytelling in biopharmaHEOR and real-world evidence (RWE)Value communication for payers and HTAsMarket access strategy Guests: Kate Lothman, Director of Medical Writing & PublicationsSara Musetti Jenkins, Principal Medical WriterJason Crouch, Graphic Designer

    18 分鐘

  4. 5月8日

    Putting Patients First: Patient-Centered Evidence & PROs in Biopharma

    This episode is part one of a three-part series featured on Fierce Pharma’s The Top Line podcast. What does it really mean to put patients first in biopharma? In this episode of Pharma Unscripted, we explore how patient-centered evidence, including patient-reported outcomes (PROs), is reshaping clinical development, regulatory expectations, and market access. As decision-makers look beyond traditional endpoints, understanding the real patient experience, quality of life, treatment burden, and daily impact, is becoming essential. Key Topics: Patient-reported outcomes (PROs)Patient-centered evidence generationClinical trial design and endpointsMarket access and patient experience Guests: Ash Menon, Sr. Medical Affairs LeadMark Price, Head of Expert Perspectives

    28 分鐘
  • 4 集

關於

Pharma Unscripted explores how evidence is evolving across the biopharma landscape—and what that means for patients, access, and decision-making. Through expert-led conversations, the series examines how organizations are generating and applying evidence to bring meaningful therapies to the people who need them most. From patient-centered outcomes and real-world evidence to value demonstration and AI in medical communications, each episode breaks down the trends shaping how therapies move from development to real-world impact.

資料

  • 創作者
    RTI Health Solutions
  • 活躍年份
    2026年
  • 單集
    4
  • 分級
    兒童適宜
  • 版權
    © 2026 RTI Health Solutions
  • 節目網站
    Pharma Unscripted